Download PDF
Thromb Haemost 2006; 95(04): 752-754
DOI: 10.1160/TH05-10-0657
Letters to the Editor
Schattauer GmbH

The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma

Mario Mandalà
1   Division of Medical Oncology, Treviglio-Caravaggio Hospital, Italy
,
Anna Falanga
2   Division of Hematology, Ospedali Riuniti di Bergamo, Italy
,
Marc Cremonesi
1   Division of Medical Oncology, Treviglio-Caravaggio Hospital, Italy
,
Maurizio Zaccanelli
3   Unit of Transfusion and Hematology, Treviglio Hospital, Italy
,
Irene Floriani
4   Division of Oncology, Istituto Mario Negri, Milan, Italy
,
Maria Grazia Viganò
5   Division of Medical Oncology, S. Raffaele Hospital, Milan, Italy
,
Alberto Rosti
3   Unit of Transfusion and Hematology, Treviglio Hospital, Italy
,
Maria Elena Cazzaniga
1   Division of Medical Oncology, Treviglio-Caravaggio Hospital, Italy
,
Gianluigi Ferretti
6   Division of Medical Oncology, Ospedale Regina Elena Rome, Italy
,
Mary Cabiddu
1   Division of Medical Oncology, Treviglio-Caravaggio Hospital, Italy
,
Sandro Barni
1   Division of Medical Oncology, Treviglio-Caravaggio Hospital, Italy
› Author Affiliations
Further Information

Publication History

Received 06 October 2005

Accepted after resubmission 20 February 2006

Publication Date:
30 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Falanga A, Rickels FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25: 173-82.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Di Micco P, Romano M, Niglio A. et al. Alteration of haemostasis in non-metastatic gastric cancer. Dig Liver Dis 2001; 33: 546-50.
    CrossrefPubMedGoogle Scholar
  • 3 Otten HM, Mathijssen J, ten Cate H. et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy, an understimated phenomenon. Arch Intern Med 2004; 164: 190-4.
    CrossrefPubMedGoogle Scholar
  • 4 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-31.
    CrossrefPubMedGoogle Scholar
  • 5 Mandalà M, Curigliano G, Bucciarelli P. et al. FactorV Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004; 15: 590-3.
    CrossrefPubMedGoogle Scholar
  • 6 Blom J, Doggen CJM, Osanto S. et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
    CrossrefPubMedGoogle Scholar
  • 7 Levine MN, Gent M, Hirsh J. et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-7.
    CrossrefPubMedGoogle Scholar
  • 8 von Tempelhoff GF, Dietrich M, Hommel G. et al. Blood coagulation during adjuvant epirubicin cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol 1996; 14: 2560-8.
    CrossrefPubMedGoogle Scholar
  • 9 Sifontes MT, Nuss R, Hunger SP. et al. The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 1997; 96: 484-9.
    CrossrefPubMedGoogle Scholar
  • 10 Rees D, Grimwade D, Langabeer S. et al. Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia. MRC Adult Leukaemia Working Party. Br J Haematol 1997; 96: 490-2.
    CrossrefPubMedGoogle Scholar
  • 11 Mitchell LG. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase. Cancer 2003; 97: 508-16.
    CrossrefPubMedGoogle Scholar
  • 12 Pihusch R, Danzl G, Scholz M. et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 2002; 94: 3120-6.
    CrossrefPubMedGoogle Scholar